Company Encyclopedia
View More
name
SUNFLOWER
300111.SZ
Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sale of anti-infectious, cardiovascular, digestive system and other drugs worldwide. It offers clarithromycin API and tablets, an anti-infective drug used for nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, mycoplasma pneumoniae pneumonia, urethritis and cervicitis, as well as acute pharyngitis and acute tonsillitis; and azithromycin dispersible tablets for sinusitis, acute otitis media, acute bronchitis, acute exacerbation of chronic bronchitis, streptococcus pneumoniae, pneumonia, haemophilus influenzae, mycoplasma pneumoniae, urethritis, cervicitis and skin and soft tissue infection. The company also provides roxithromycin capsules to treat otitis, acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia caused by mycoplasma pneumoniae or chlamydia pneumoniae, urethritis, cervicitis, and skin and soft tissue infection.
3.157 T
300111.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking105/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE0.93%D
    • Profit Margin2.10%C
    • Gross Margin24.35%C
  • Growth ScoreC
    • Revenue YoY-8.28%D
    • Net Profit YoY956.47%A
    • Total Assets YoY-4.63%D
    • Net Assets YoY1.40%C
  • Cash ScoreC
    • Cash Flow Margin4771.65%A
    • OCF YoY-8.28%D
  • Operating ScoreD
    • Turnover0.31D
  • Debt ScoreA
    • Gearing Ratio14.76%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025

    Sunflower Pharmaceutical Group Co., Ltd reported a significant decline in earnings for the nine months ended September 30, 2025. Sales dropped to CNY 1,683.98 million from CNY 2,966.91 million year-over-year. The company faced a net loss of CNY 33.54 million, contrasting with a net income of CNY 586.84 million in the previous year. Basic and diluted loss per share from continuing operations were both CNY 0.06, down from earnings of CNY 1 per share a year ago.

    marketscreener·
    SZ
    300111
    +0.69%
    marketscreener·
    SZ
    300111
    +0.69%

    SUNFLOWER released its performance for the first three quarters, with a net profit attributable to the parent company of 1.3062 million yuan, a decrease of 53.10%

    According to the Zhitong Finance APP, SUNFLOWER released its Q3 2025 report, stating that the company's operating revenue for the first three quarters was 200 million yuan, a year-on-year decrease of 12.09%. The net profit attributable to shareholders of the listed company was 1.3062 million yuan, a year-on-year decrease of 53.10%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 93,300 yuan. The basic earnings per share were 0.001 yuan

    Zhitong·
    SZ
    300111
    +0.69%
    Zhitong·
    SZ
    300111
    +0.69%

    Sunflower Pharmaceutical Gets China Clinical Trial Approval for Bronchitis Drug for Kids

    Sunflower Pharmaceutical Gets China Clinical Trial Approval for Bronchitis Drug for Kids

    marketscreener·
    SZ
    300111
    +0.69%
    marketscreener·
    SZ
    300111
    +0.69%

    Institutions sold Tianji Holdings and 14 other stocks today, buying SUNFLOWER for 130 million yuan

    On October 16th, a total of 23 stocks appeared on the leaderboard, among which 8 stocks achieved net purchases and 15 stocks experienced net sales. The top three stocks with net purchases were SUNFLOWER (CNY 130 million), iCkey (CNY 95.61 million), and Zhongdian Xinlong (CNY 47.85 million); the top three stocks with net sales were Tianji Shares (CNY 217 million), Hubei Yihua (CNY 153 million), and Beifang Changlong (CNY 138 million)

    36Kr·
    SZ
    300111
    +0.69%
    SZ
    301563
    +1.05%
    36Kr·
    SZ
    300111
    +0.69%
    SZ
    301563
    +1.05%

    The pharmaceutical sector fell at the beginning of trading, with SUNFLOWER dropping 10%

    The pharmaceutical sector fell at the beginning of trading, with SUNFLOWER dropping 10%, ASK PHARM falling over 7%, and multiple stocks including Staidson BioPharm, Hengrui Pharma, and EASTON BIOPHARMACEUTICALS declining

    Zhitong·
    SZ
    300204
    +1.32%
    SH
    600276
    +0.60%
    SH
    688513
    +0.09%
    Zhitong·
    SZ
    300204
    +1.32%
    SH
    600276
    +0.60%
    SH
    688513
    +0.09%
    Posts
    View More

    $XTALPI(02228.HK) A familiar friend will accompany the chairman of PharmaTech Holdings to Dubai at the end of the month, mainly for the desert project, and will bring more first-hand information about...

    • 0
    © 2025 Longbridge｜Disclaimer